November 21, 2019

Tonix Pharmaceuticals Begins Phase 3 RELIEF Study

The company announced that its Phase 3 RELIEF Study will evaluate its TNX-102- SL in patients with fibromyalgia.
August 20, 2019

Tonix Pharmaceuticals Expands Preclinical Pipeline

Tonix Pharmaceuticals Holding (NASDAQ:TNXP) has announced an exclusive agreement to in-license a triple reuptake inhibitor, TNX-1600, to treat post-traumatic stress...